CSPC Pharmaceutical Group Ltd (CHPTY) Raised to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) from a sell rating to a hold rating in a report released on Thursday.
According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “
CSPC Pharmaceutical Group (NASDAQ CHPTY) opened at 73.27 on Thursday. The firm has a market cap of $8.87 billion and a PE ratio of 29.31. CSPC Pharmaceutical Group has a 52-week low of $50.09 and a 52-week high of $73.36. The company’s 50 day moving average price is $73.27 and its 200 day moving average price is $68.09.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/04/cspc-pharmaceutical-group-ltd-chpty-raised-to-hold-at-zacks-investment-research.html.
CSPC Pharmaceutical Group Company Profile
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related stocks with our FREE daily email newsletter.